NTLA
Price
$7.69
Change
+$0.53 (+7.40%)
Updated
Jun 3, 04:59 PM (EDT)
Capitalization
796.56M
58 days until earnings call
RXRX
Price
$4.38
Change
+$0.01 (+0.23%)
Updated
Jun 3, 04:59 PM (EDT)
Capitalization
1.78B
70 days until earnings call
Interact to see
Advertisement

NTLA vs RXRX

Header iconNTLA vs RXRX Comparison
Open Charts NTLA vs RXRXBanner chart's image
Intellia Therapeutics
Price$7.69
Change+$0.53 (+7.40%)
Volume$108.25K
Capitalization796.56M
Recursion Pharmaceuticals
Price$4.38
Change+$0.01 (+0.23%)
Volume$266.42K
Capitalization1.78B
NTLA vs RXRX Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTLA vs. RXRX commentary
Jun 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Buy and RXRX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 04, 2025
Stock price -- (NTLA: $7.16 vs. RXRX: $4.37)
Brand notoriety: NTLA and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 184% vs. RXRX: 89%
Market capitalization -- NTLA: $796.56M vs. RXRX: $1.78B
NTLA [@Biotechnology] is valued at $796.56M. RXRX’s [@Biotechnology] market capitalization is $1.78B. The market cap for tickers in the [@Biotechnology] industry ranges from $321.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whileRXRX’s FA Score has 0 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, both NTLA and RXRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 5 TA indicator(s) are bullish while RXRX’s TA Score has 5 bullish TA indicator(s).

  • NTLA’s TA Score: 5 bullish, 4 bearish.
  • RXRX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, RXRX is a better buy in the short-term than NTLA.

Price Growth

NTLA (@Biotechnology) experienced а -21.83% price change this week, while RXRX (@Biotechnology) price change was +7.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.48%. For the same industry, the average monthly price growth was +5.47%, and the average quarterly price growth was +1.42%.

Reported Earning Dates

NTLA is expected to report earnings on Jul 31, 2025.

RXRX is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+8.48% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($1.79B) has a higher market cap than NTLA($797M). RXRX YTD gains are higher at: -35.355 vs. NTLA (-38.593). RXRX (-524.77M) and NTLA (-530.8M) have comparable annual earnings (EBITDA) . NTLA (504M) and RXRX (500M) have equal amount of cash in the bank . RXRX has less debt than NTLA: RXRX (92.9M) vs NTLA (119M). RXRX has higher revenues than NTLA: RXRX (59.8M) vs NTLA (45.6M).
NTLARXRXNTLA / RXRX
Capitalization797M1.79B45%
EBITDA-530.8M-524.77M101%
Gain YTD-38.593-35.355109%
P/E RatioN/AN/A-
Revenue45.6M59.8M76%
Total Cash504M500M101%
Total Debt119M92.9M128%
FUNDAMENTALS RATINGS
NTLA: Fundamental Ratings
NTLA
OUTLOOK RATING
1..100
3
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
94
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NTLARXRX
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
69%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 7 days ago
77%
Bullish Trend 6 days ago
84%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 20 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
USLCX43.79N/A
N/A
JHancock U.S. Global Leaders Growth C
WSEFX34.69N/A
N/A
Boston Trust Walden Equity
WPCSX46.82N/A
N/A
AB Concentrated Growth C
TRZRX14.93N/A
N/A
T. Rowe Price Real Assets Z
BAILX12.03N/A
N/A
Brown Advisory Sustainable Intl Ldrs Ins